November 30, 2016 - By Marguerite Chambers
In a research report revealed to investors on 30 November, Astrazeneca (LON:AZN) stock had its Buy Rating maintained by stock research analysts at Deutsche. They currently have a GBX 6000.00 PT on firm. Deutsche’s target gives a potential upside of 43.78% from the company’s last stock close price.
Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4911.37 average target is 18.06% above today’s (GBX 4160) stock price. AstraZeneca PLC has been the topic of 342 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Natixis maintained AstraZeneca plc (LON:AZN) on Wednesday, February 24 with “Neutral” rating. The stock of AstraZeneca plc (LON:AZN) earned “Outperform” rating by BNP Paribas on Monday, December 7. The stock of AstraZeneca plc (LON:AZN) earned “Buy” rating by Deutsche Bank on Monday, February 8. The firm has “Buy” rating by Jefferies given on Wednesday, September 21. Deutsche Bank maintained AstraZeneca plc (LON:AZN) rating on Thursday, March 24. Deutsche Bank has “Buy” rating and GBX 5600 price target. On Friday, October 28 the stock rating was maintained by HSBC with “Hold”. The stock has “Buy” rating given by HSBC on Monday, January 4. The company was maintained on Thursday, October 27 by Goldman Sachs. The stock of AstraZeneca plc (LON:AZN) has “Hold” rating given on Thursday, August 11 by Shore Capital. As per Thursday, September 10, the company rating was maintained by Deutsche Bank.
About 2.24M shares traded hands. AstraZeneca plc (LON:AZN) has risen 8.10% since May 2, 2016 and is uptrending. It has outperformed by 2.87% the S&P500.
Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 earnings per share, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.42B for 11.54 P/E if the $0.57 EPS becomes a reality. After $1.32 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.
AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 52.88 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 26.51 P/E ratio. The Firm has its activities in over 100 countries.
According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.
Another recent and important AstraZeneca plc (LON:AZN) news was published by Schaeffersresearch.com which published an article titled: “Analyst Upgrades: Apple Inc., AstraZeneca plc, and Ctrip.com International, Ltd.” on November 25, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.